178 related articles for article (PubMed ID: 25843293)
41. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
42. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
43. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
[TBL] [Abstract][Full Text] [Related]
44. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
45. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
Charlet J; Szemes M; Malik KT; Brown KW
Mol Carcinog; 2014 May; 53(5):413-20. PubMed ID: 23280764
[TBL] [Abstract][Full Text] [Related]
46. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
47. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
48. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
49. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
Foley NH; Bray IM; Tivnan A; Bryan K; Murphy DM; Buckley PG; Ryan J; O'Meara A; O'Sullivan M; Stallings RL
Mol Cancer; 2010 Apr; 9():83. PubMed ID: 20409325
[TBL] [Abstract][Full Text] [Related]
51. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
Iraci N; Diolaiti D; Papa A; Porro A; Valli E; Gherardi S; Herold S; Eilers M; Bernardoni R; Della Valle G; Perini G
Cancer Res; 2011 Jan; 71(2):404-12. PubMed ID: 21123453
[TBL] [Abstract][Full Text] [Related]
52. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
53. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
54. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
55. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
[TBL] [Abstract][Full Text] [Related]
56. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
58. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
59. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.
Tang Y; Simoneau AR; Liao WX; Yi G; Hope C; Liu F; Li S; Xie J; Holcombe RF; Jurnak FA; Mercola D; Hoang BH; Zi X
Mol Cancer Ther; 2009 Feb; 8(2):458-68. PubMed ID: 19174556
[TBL] [Abstract][Full Text] [Related]
60. MycN is a transcriptional regulator of livin in neuroblastoma.
Dasgupta A; Peirce SK; Findley HW
Oncol Rep; 2009 Oct; 22(4):831-5. PubMed ID: 19724862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
